Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.
Glucocorticoids
Immune System Diseases
Inflammation
Therapeutics
Tumor Necrosis Factor Inhibitors
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
09 Dec 2023
09 Dec 2023
Historique:
received:
07
08
2023
accepted:
22
10
2023
medline:
10
12
2023
pubmed:
10
12
2023
entrez:
10
12
2023
Statut:
aheadofprint
Résumé
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors. Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models. Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the
Identifiants
pubmed: 38071510
pii: ard-2023-224819
doi: 10.1136/ard-2023-224819
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Isabelle Melki
(I)
Pierre Fenaux
(P)
Lionel Ades
(L)
Alexandra Audemard
(A)
Mikael Ebbo
(M)
Yvan Jamilloux
(Y)
Odile Beyne Rauzy
(OB)
Alexandre Belot
(A)
Raphaël Borie
(R)
Alexis Mathian
(A)
Laurent Arnaud
(L)
François Chasset
(F)
Jean-David Bouaziz
(JD)
Pierre Sujobert
(P)
Ygal Benhamou
(Y)
Gaetan Sauvetre
(G)
Khalil El-Karoui
(K)
François Rodrigues
(F)
Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.